Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/22/2024 | $55.00 | Overweight | Wells Fargo | |
7/17/2024 | $19.00 | Buy | Jefferies | |
6/26/2024 | Overweight | Piper Sandler | ||
6/24/2024 | Buy | TD Cowen | ||
4/4/2024 | Overweight | Cantor Fitzgerald | ||
2/12/2024 | $18.00 | Overweight | Piper Sandler | |
12/8/2023 | $16.00 | Buy | B. Riley Securities | |
10/20/2022 | $10.00 | Neutral → Buy | H.C. Wainwright |
Leerink Partners analyst David Risinger initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Outperform rating and announces Price Target of $49.
Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Price Target of $19.
Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00
Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00
Piper Sandler initiated coverage of Tectonic Therapeutic with a rating of Overweight
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in September. 2024 Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 12:45 PM ET Location: Boston, MA 2024 Cantor Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 9:10 AM ET Location: New York, NY A live webcast of the presentations will be available under the "Events & Presentations" tab on the "In
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024. 2024 Wells Fargo Healthcare Conference:Date:September 4, 2024Time:3:45 PM ETPresenter:Alise Reicin, MD, President, CEO and Director,
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech
144 - Tango Therapeutics, Inc. (0001819133) (Subject)
144 - Tango Therapeutics, Inc. (0001819133) (Subject)
144 - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)
4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed